SU SURAKSHA
Suraksha Diagnostic Q3 2026
SUSURAKSHA

Suraksha Diagnostic Q3 FY26 results (Oct–Dec 2025) and concall

Healthcare · Concall AI · Call held 6 Feb 2026

Management summary

  • Suraksha Diagnostic Limited reported robust Q3 FY26 results with total income growing 30.3% YoY to INR 783.09 million.
  • Strong volume growth and strategic expansion into genomics..
  • While EBITDA margins compressed temporarily to 30.6% due to new center ramp-up costs, management is focused on achieving scale and expects margin improvement from Q3 FY27.
  • The company is aggressively expanding its network and strengthening its genomics vertical, maintaining a healthy net cash position.

Source: Inve concall analysis and management guidance record.

Highlights

  • Total income for Q3 FY26 grew by a solid 30.3% year-on-year to INR 783.09 million, driven by volume expansion and product mix.

  • Tests performed in Q3 FY26 increased by 30.7% year-over-year to 2.06 million, indicating strong operational growth.

  • The company successfully commissioned 12 new centers in nine months, with an additional 6 facilities in the execution phase.

  • The genomics and molecular vertical, 'Suraksha Sutra,' has shown positive clinical adoption, with a current run rate of INR 2.1-2.2 million per month and a target of INR 4+ crores for FY27.

What they filed

Q3 FY26: revenue up 28.8%, net profit up 33.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue59 64 70 76 76 +29%
EBITDA18 20 24 24 23 +28%
Net profit6 8 10 9 8 +33%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue

  • FY26 Revenue Growth Revenue · FY26 · High confidence better than 15%

    Previously 15% → better than 15%

Margin

  • FY26 EBITDA Margin Margin · FY26 · High confidence around 32%

    Previously 33-34% → around 32%

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

2 direct
Q3 EBITDA Margins and Seasonality Direct
The Q3 margins are always the quarter three is the weakest quarter in healthcare. That is almost a given for... it's a seasonal thing basically and that's almost a given for any kind of healthcare anywhere.

Clarifies that the lower Q3 EBITDA margins are a seasonal effect common in the healthcare industry, not a company-specific issue.

Asked by Dhruv Maheshwari

Current Run Rate for Genomics Business Direct
So currently what we are running at is around INR2.1, INR2.2 million a month we are running. So last quarter Q3 we kind of reached at around INR53 lakhs.

Provides specific, current financial performance data for the high-growth genomics segment, which is a key strategic focus.

Asked by Dhruv Maheshwari

Unlock risks & concerns, Q4 FY26 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 6 risks, concerns & management red flags
  • 5 watchlist triggers for Q4 FY26
  • +6 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image